Oncobiologics, Inc. is a research and development company focusing on low cost innovative oncology and immunology biopharmaceutical treatments for patients located in Cranbury, New Jersey. Oncobiologics is actively partnering with best-in-class research centers and top-tier pharmaceutical organizations to advance its mission of increasing the flow of biologics to the patients who need them. The company is staffed by veterans from industry leaders including Genetech, Amgen, Eli Lilly, Bristol Myers Squibb, Bayer, Merck, Johnson & Johnson, Schering-Plough and Medarex.
The founder and CEO, Dr. Pankaj Mohan, has an extensive background in the pharmaceutical industry. An industry leader with over 20 years of multicompany biopharmaceutical industrial experience at Genentech, Eli Lilly and BMS; and in an academic center of excellence in Bioprocess Engineering (Assistant Prof., University College London). He has played an important role in industry in the development and manufacture of blockbuster biologics entities including: Belatacept, Orencia, Erbitux, Avastin, Rituxan, Herceptin, Lucentis, Xigris , Human Growth Hormone and Insulin.
Dr. Mohan has a Bachelor’s degree in Chemical Engineering from IIT, India; PhD in Biochemical Engineering (Birmingham, UK), MBA, Finance (London, UK) and an executive education from Fuqua Business School, Duke University, USA. He has published a book “Pharmaceutical Operations” with McGraw-Hill and has over 30 publications, and will soon publish the first “Biopharmaceuticals Handbook”.
The company received a $1 million dollar SBA loan. “We are very grateful for the assistance and services provided by experts at the NJSBDC at Raritan Valley Community College,” said Dr. Pankaj Mohan, “Their guidance with the formulation of our business plan and referrals for company human resources needs as well as identifying the right lenders led to the successful approval of a loan which will help develop and launch cancer therapy at low cost.”
The company also received a 4 million dollar Qualifying Therapeutic Discovery Project Program grant to assist the company. The company has created 25 new jobs and will create another 35 jobs by spring 2012.
7 Clarke Drive
Cranbury, NJ 08512